好消息！新冠药物落地河南，我国自主研发新抗病毒药物阿兹夫定片上市

At present, with the rapid spread of the epidemic at home and abroad, our country has done a good job in controlling the new crown epidemic. It has been three years since the epidemic started in 2019. More people hope that the epidemic will pass soon. Just yesterday, there was good news for the new crown epidemic. There was a first treatment for the new crown epidemic. A domestically produced drug, Medical Travel was informed that the official website of the National Medical Products Administration (NMPA) showed that in accordance with the special drug approval procedures, emergency review and approval was carried out, and Henan Real Biotechnology Co., Ltd.’s application for registration of Azivudine Tablets for additional indications for the treatment of new coronavirus pneumonia was conditionally approved.

(pixabay)

my country's independent research on antiviral drugs has begun in Henan

Azivudine tablets are an oral small molecule COVID-19 treatment drug independently developed in my country. At this great moment, we have witnessed a miracle. Henan Real Biotechnology released the results of the Phase III clinical trial of Azivudine. Azivudine tablets can significantly shorten the symptom improvement time of patients with moderate novel coronavirus-infected pneumonia, increase the proportion of patients with improved clinical symptoms, and achieve clinical superior results. The proportion of subjects whose clinical symptoms improved on the 7th day after the first administration was 40.43% in the Azivudine group and 10.87% in the placebo group (P value <0.001). The median time to improvement of clinical symptoms among subjects was significantly statistically different between the Azivudine group and the placebo group (P value <0.001). Azivudine has the effect of inhibiting the activity of the new coronavirus, and the virus clearance time is about 5 days.

Why is an innovative drug for the treatment of AIDS effective against the new coronavirus?

Azivudine can treat AIDS and has a broad-spectrum effect on inhibiting the replication of RNA viruses. Although the new coronavirus is different from HIV, it is both a virus with RNA as its genetic material. Azivudine, as a nucleoside analog that inhibits viral RNA-dependent RNA polymerase (RdRp), can specifically act on the RdRp of the new coronavirus, thereby inhibiting viral replication. Its drug is highly targeted and long-lasting, so it is also effective against the new coronavirus.

Drugs launched abroad to treat COVID-19

As early as last year, on December 22, 2021, Pfizer announced that the United States (FDA) had granted PAXLOVID emergency use authorization for the treatment of adult and pediatric patients (12 years and older and at least 40 kg) with mild to moderate COVID-19 who have a positive direct test result for the SARS-CoV-2 virus and are at higher risk of developing severe COVID-19, including hospitalization or death.

The domestic launch of the new coronavirus drug Azivudine also confirms the power of my country's research and development medical community. Although we do not want more people to be infected with the virus, it also provides treatment opportunities for patients infected with the new coronavirus. We hope that the world will overcome the virus as soon as possible, open the door to the country, and restore the economy.

Source

[1]National Medical Products Administration

[2]Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.